CorMedix Inc. (NYSEMKT:CRMD) had its target price dropped by equities research analysts at FBR & Co from $6.00 to $4.00 in a research note issued to investors on Friday. The firm currently has an “outperform” rating on the stock. FBR & Co’s price target points to a potential upside of 116.22% from the stock’s previous close.

Separately, Zacks Investment Research upgraded CorMedix from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research report on Monday, July 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. CorMedix currently has an average rating of “Buy” and an average target price of $4.75.

Shares of CorMedix (NYSEMKT:CRMD) opened at 1.85 on Friday. CorMedix has a 1-year low of $1.15 and a 1-year high of $4.54. The stock’s 50 day moving average price is $2.43 and its 200 day moving average price is $2.30. The stock’s market cap is $68.80 million.

In other CorMedix news, Director Janet Dillione purchased 15,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The shares were purchased at an average cost of $2.66 per share, with a total value of $39,900.00. Following the completion of the transaction, the director now owns 15,000 shares of the company’s stock, valued at $39,900. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Taunia Markvicka purchased 18,600 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $30,690.00. Following the completion of the transaction, the director now directly owns 22,600 shares of the company’s stock, valued at approximately $37,290. The disclosure for this purchase can be found here.

A number of hedge funds and other institutional investors have recently bought and sold shares of CRMD. Private Advisor Group LLC raised its position in CorMedix by 14.2% in the second quarter. Private Advisor Group LLC now owns 108,333 shares of the company’s stock valued at $195,000 after buying an additional 13,500 shares during the last quarter. Vanguard Group Inc. raised its position in CorMedix by 0.7% in the second quarter. Vanguard Group Inc. now owns 1,112,569 shares of the company’s stock valued at $2,214,000 after buying an additional 7,519 shares during the last quarter. Bridgeway Capital Management Inc. raised its position in CorMedix by 1.7% in the second quarter. Bridgeway Capital Management Inc. now owns 279,701 shares of the company’s stock valued at $557,000 after buying an additional 4,600 shares during the last quarter. Paloma Partners Management Co raised its position in CorMedix by 746.1% in the second quarter. Paloma Partners Management Co now owns 132,864 shares of the company’s stock valued at $264,000 after buying an additional 117,160 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in CorMedix by 21.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 601,921 shares of the company’s stock valued at $1,517,000 after buying an additional 106,999 shares during the last quarter.

About CorMedix

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Stock Ratings for CorMedix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix Inc. and related stocks with our FREE daily email newsletter.